MarkEdwardBurkardMDPhD

PubMed

• A survey of chromosomal instability measures across mechanistic models.
  Andrew R Lynch, Shermineh Bradford, Amber S Zhou, Kim Oxendine, Les Henderson, Vanessa L Horner, Beth A Weaver, Mark E Burkard> ;Proceedings of the National Academy of Sciences of the United States of America. 2024 Apr 16
• 1 citations
  The reckoning of chromosomal instability: past, present, future.
  Andrew Lynch, Shermineh Bradford, Mark E Burkard> ;Chromosome Research. 2024 Feb 17
• ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
  Clayton T Marcinak, Roberto J Vidri, Amy K Taylor, John K Krebsbach, Kaleem S Ahmed, Noelle K LoConte, Patrick R Varley, Majid Afshar, Sharon M Weber, Daniel E Abbott,...> ;Annals of Surgical Oncology. 2024 Jan 1
• Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
  Clayton T Marcinak, Roberto J Vidri, Amy K Taylor, John K Krebsbach, Kaleem S Ahmed, Noelle K LoConte, Patrick R Varley, Majid Afshar, Sharon M Weber, Daniel E Abbott,...> ;Annals of Surgical Oncology. 2024 Jan 1
• 1 citations
  Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
  Sean R O'Neil, Garrett A Weber, Dustin A Deming, Mark E Burkard, Paraic A Kenny, Craig S Richmond, Benjamin M Parsons> ;JCO Precision Oncology. 2023 Jul 1
• Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
  Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William J Edenfield, Elizabeth Claire Dees, ...> ;Cancer Research Communications. 2023 Jul 1
• 1 citations
  A survey of CIN measures across mechanistic models.
  Andrew R Lynch, Shermineh Bradford, Amber S Zhou, Kim Oxendine, Les Henderson, Vanessa L Horner, Beth A Weaver, Mark E Burkard> ;Biorxiv. 2023 Jun 15
• Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy.
  Clayton T Marcinak, William F Parker, Alexander A Parikh, Jashodeep Datta, Shishir K Maithel, David A Kooby, Mark E Burkard, Hong Jin Kim, Michael T LeCompte, Majid Af...> ;Journal of Surgical Oncology. 2023 Aug 1
• 6 citations
  Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
  Tomlins, S., Khazanov, N., Bulen, B., Hovelson, D., Shreve, M., Lamb, L., Matrana, M., Burkard, M., Yang, E., Edenfield, W., Dees, E., Onitilo, A., Thompson, M., Buchs...> ;Communications Medicine. 2023 Feb 7
• 3 citations
  Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
  Anne L Loeser, Lucy Gao, Aditya Bardia, Mark E Burkard, Kevin M Kalinsky, Jeffrey Peppercorn, Hope S Rugo, Martha Carlson, Janice Cowden, Lesley Glenn, Julia Maues, Sh...> ;Breast Cancer Research and Treatment. 2022 Dec 1
• 6 citations
  Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference.
  Andrew R Lynch, Nicholas L Arp, Amber S Zhou, Beth A Weaver, Mark E Burkard> ;Elife. 2022 Apr 5
• 4 citations
  Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.
  Keng Hee Peh, Daniel J Przybylski, Michael J Fallon, Jason J Bergsbaken, Paul R Hutson, Menggang Yu, Dustin A Deming, Mark E Burkard> ;Journal of Oncology Pharmacy Practice. 2023 Jul 1
• 2 citations
  Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays
  Melissa C. Skala, Jose M. Ayuso, Mark E. Burkard, Dustin A. Deming> ;Current Opinion in Biomedical Engineering. 2022 Mar 1
• 2 citations
  Increased Aurora B expression reduces substrate phosphorylation and induces chromosomal instability.
  Eric M C Britigan, Jun Wan, Daniel K Sam, Sarah E Copeland, Amber L Lasek, Laura C F Hrycyniak, Lei Wang, Anjon Audhya, Mark E Burkard, Avtar Roopra, Beth A Weaver> ;Frontiers in Cell and Developmental Biology. 2022 Jan 1
• 1 citations
  Classes of therapeutics to amplify the immune response.
  Yang Hu, Mark E. Burkard> ;Breast Cancer Research and Treatment. 2021 Nov 17
• 27 citations
  Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
  Yang Hu, Baraa K. Manasrah, Stephanie M. McGregor, Robert F. Lera, Roshan X. Norman, John B. Tucker, Christina M. Scribano, Rachel E. Yan, Mouhita Humayun, Kari B. Wis...> ;Molecular Cancer Therapeutics. 2021 Sep 28
• 39 citations
  Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel
  Christina M. Scribano, Jun Wan, Karla Esbona, John B. Tucker, Amber Lasek, Amber S. Zhou, Lauren M. Zasadil, Ryan Molini, Jonathan Fitzgerald, Angela M. Lager, Jennife...> ;Science Translational Medicine. 2021 Sep 8
• 13 citations
  Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
  Scott A. Tomlins, Daniel H. Hovelson, Jennifer Marie Suga, Daniel M. Anderson, Han A. Koh, Elizabeth Claire Dees, Brendan McNulty, Mark E. Burkard, Michael Guarino, Ja...> ;JCO Precision Oncology. 2021 Aug 19
• 41 citations
  E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer...
  Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown-Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. O...> ;Journal of Clinical Oncology. 2021 Aug 6
• 4 citations
  Centriole and Golgi microtubule nucleation are dispensable for the migration of human neutrophil-like cells
  Lucas C. Klemm, Ryan A. Denu, Laurel E. Hind, Briana L. Rocha-Gregg, Mark E. Burkard, Anna Huttenlocher> ;Molecular Biology of the Cell. 2021 Jun 30
• 5 citations
  Compensatory expression of NRF2-dependent antioxidant genes is required to overcome the lethal effects of Kv11.1 activation in breast cancer cells and PDOs.
  Vitalyi Senyuk, Najmeh Eskandari, Ying Jiang, Rebeca García-Varela, Rachel Sundstrom, Luigi Leanza, Roberta Peruzzo, Mark E. Burkard, Richard D. Minshall, Saverio Gentile> ;Redox Biology. 2021 Jun 12
• 14 citations
  High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosom...
  Daniel R. Matson, Ryan A. Denu, Lauren M. Zasadil, Mark E. Burkard, Beth A. Weaver, Christopher Flynn, P. Todd Stukenberg> ;BMC Cancer. 2021 Feb 23
• 7 citations
  CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets
  Matthew N. Bernstein, Zijian Ni, Michael Collins, Mark E. Burkard, Christina Kendziorski, Ron Stewart> ;BMC Bioinformatics. 2021 Feb 23
• 4 citations
  Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
  Aidan Gilbert, Courtney P. Williams, Andres Azuero, Mark E. Burkard, Kelly M. Kenzik, Elizabeth Garrett-Mayer, Stephen C. Meersman, Gabrielle B. Rocque> ;Clinical Breast Cancer. 2021 Aug 1
• 8 citations
  Visualization of Sequential Treatments in Metastatic Breast Cancer.
  Gabrielle B. Rocque, Pravinkumar G Kandhare, Courtney P. Williams, Arie Nakhmani, Mark E. Burkard, Andres Forero, Kelly M. Kenzik, > ;JCO Clinical Cancer Informatics. 2020 Sep 1
• Join now to see all

Journal Articles

• Efficacy of Selpercatinib in RET-Altered Thyroid Cancers  
  Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine

Lectures

• How Does the Practicing Oncologist Make Sense of a Genomic Report? 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018